Application

Anti-EEA1 antibody, Mouse monoclonalhas been used in:immunoblottingimmunoprecipitation cell fractionationindirect immunofluorescenceimmunohistochemistry

Monoclonal Anti-EEA1 antibody produced in mouse is suitable for the following applications: Immunoprecipitation Indirect immunofluorescence Western blotting at a concentration of 1-2µg/mL using whole extract of rat NRK cells

Biochem/physiol Actions

Early Endosome Antigen 1 (EEA1) controls vesicle fusion during endocytosis. In neurons, it is involved in recycling of synaptic vesicles and neurotransmitter receptors. Patients with neurological deficits develop EEA1 autoantibodies. Mutation in EEA1 gene leads to susceptibility to diabetes in the Japanese population. Phosphatidylinositol 3-phosphate (PtdIns(3)P) is essential for the localization and function of EEA1.

Early Endosome Antigen 1 (EEA1) FYVE domain is involved in intracellular trafficking and is implicated in the specific localization of EEA1 to endosomes . Endosomal targeting of EEA1 also requires its binding to the active form of the small GTPase Rabaptin-5 (Rab5). The binding of EEA1 to phosphatidylinositol 3-phosphate (PtdIns 3P) and Rab5-GTP is essential for the localization and function of EEA1 in endocytic membrane fusion. Monoclonal Anti-EEA1 may be used as an early endosome marker.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

The gene Early Endosome Antigen 1 (EEA1) encodes for around 1400 amino acid proteins. It is a peripheral membrane protein associated with the cytoplasmic face of early endosomes. EEA1 is a autoantigen associated with subacute cutaneous systemic lupus erythematosus and is a coiled-coil protein localized to early endosomes and cytosol.

Monoclonal Anti-EEA1 (mouse IgG2a isotype) is derived from the hybridoma EEA1-N19 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a synthetic peptide corresponding to a fragment of human EEA1. Early Endosome Antigen 1 (EEA1) is a dimer. It comprises extensive coiled-coil regions, and at its C-terminus contains a cysteine-rich zinc-finger-like domain named FYVE domain.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.